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ABSTRACT OF DISSERTATION  
 
 
 
 
ROLE OF MEL-18 IN REGULATING PROTEIN SUMOYLATION AND 
IDENTIFICATION OF A NEW POLYMORPHISM IN BMI-1 
 
Small ubiquitin-like modifier (SUMO) regulates numerous biological 
functions. In a previous study we found that sumoylation of HSF2 is involved in 
regulating HSF2 bookmarking function, but the mechanism that mediates this 
regulation was unknown. The results in my work support the intriguing hypothesis 
that polycomb protein, Mel-18, actually functions as an anti-SUMO E3 protein, 
interacting both with HSF2 and the SUMO E2 Ubc9, but acting to inhibit Ubc9 
activity and thereby decrease sumoylation of the HSF2. 
This study also suggested that Mel-18 negatively regulates the sumoylation 
of other cellular proteins, and we extend its targets to RanGAP1 protein. The 
results also show that RanGAP1 sumoylation is decreased during mitosis, and 
that this is associated with increased interaction between RanGAP1 and Mel-18.  
Previous studies showed little evidence of anti-SUMO E3 proteins, however,  
my study, taken together,  found Mel-18 actually functions as a novel anti-SUMO 
E3 protein, interacting both with substrates and the SUMO E2 Ubc9 but acting to 
inhibit Ubc9 activity to decrease sumoylation of target proteins and also provide 
an explanation for how mitotic HSF2/RanGAP1 sumoylation is regulated. This 
finding also gives a clue for a future study direction in Mel-18 as a tumor 
suppressor: the anti-SUMO E3 function. 
Additionally, we identify a single-nucleotide polymorphism in another human 
PcG protein, Bmi-1, that changes a cysteine residue within its RING domain, 
cysteine 18, to a tyrosine.  This C18Y polymorphism is associated with a 
significant decrease in levels of the Bmi-1 protein.  Furthermore, the C18Y Bmi-1 
protein exhibits a very high level of ubiquitination compared to wild-type Bmi-1, 
suggesting that that the low levels of this form of Bmi-1 are due to its destruction 
by the ubiquitin-proteasome system.  Consistent with this hypothesis, treatment 
of cells with the proteasome inhibitor MG-132 results in a significant increase in 
levels of C18Y Bmi-1.  This is the first example of a polymorphism in human Bmi-
1 that reduces levels of this important protein.  
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CHAPTER ONE:  
INTRODUCTION 
 
I. SUMO  
I A.      SUMO biological functions 
Small ubiquitin-like modifier (SUMO) is a protein containing 97 amino acids 
and has similar structure with ubiquitin. The modification of proteins by SUMO 
regulates numerous biological functions, such as subcellular localizations, 
protein–protein interactions and enzymatic activities. For example, SUMO 
conjugation was determined to be essential for Progressive multifocal 
leukoencephalopathy (PML) protein localization in nuclear bodies (PML NBs), 
and subcellular localizations of many other important proteins, such as heat 
shock factor 2 (HSF2), Ran GTPase-activating protein 1 (RanGAP1), P53, etc, 
are also dependent on the SUMO modifications (22). Meanwhile, interaction 
partners of these proteins will be also altered after SUMO conjugations (22,24). 
Additionally, although sumoylation results in repression of most transcription 
factors, SUMO modification appears to have a positive effect on transcriptional 
activation by the heat shock factors 1 and 2 (25,26). 
 
I B.      SUMO pathway 
There are four different ubiquitous SUMO-related proteins identified in 
mammalian cells, SUMO-1, -2, -3 and –4. SUMO-2 and SUMO-3 have greater 
sequence relatedness with each other and contain an internal consensus site for 
SUMO polymerization, which is missing in SUMO-1. SUMO-4, homologous to 
SUMO-2/3, has also been identified in human kidney as tissue-specific SUMO-4, 
indicating that some SUMO proteins could possibly have tissue-specific functions. 
Like ubiquitin, SUMO has been found to be covalently attached to certain lysine 
residues of specific target proteins containing the consensus sequence ΨKXE 
(Ψrepresents hydrophobic amino acids) by utilizing a multistep enzymatic 
pathway (Figure 1.1): SUMO protease Ulp1 cleaves SUMO into its mature form. 
Then in the activation step, SUMO is conjugated to the Uba2 subunit of the E1- 
activating heterodimer Aos1/Uba2 in an ATP-dependent manner. In the following 
conjugation step, SUMO is transferred to the E2-conjugating enzyme Ubc9. And 
in the final step, SUMO is transferred and ligated to substrate proteins by forming 
a bond between the terminal glycine on SUMO and the lysine in the target 
protein. As with other post-translational modifications, the pattern of SUMO 
conjugates is also dynamic, SUMO groups can be removed by SUMO-specific 
proteases, such as SUMO1/sentrin specific peptidase 1 (SENPs) (27). 
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I B.1.   Ubc-9 
In the conjugation step, SUMO-1 is transferred to the SUMO E2 enzyme 
Ubc9 by conjugation of its C-terminal Gly with the -SH group of the active site 
Cys93 residue on Ubc9 (28). Ubc9 structure is similar to other ubiquitin E2 
family members: an N-terminal α helix, five- to seven-stranded β sheet, the loop 
containing the catalytic cysteine (cys 93), and three C-terminal α helices (Fig 1.2). 
Mutation studies showed that residues Asp100 and Lys101 are involved in 
substrate recognition, possibly due to close to the active site Cys in the tertiary 
structure of Ubc9 (29). It was also demonstrated that the binding sites of target 
proteins on Ubc9 are around residue 129, which is near to the Cys93 in the 3-D 
structure of Ubc9. Studies also indicated that the region of first α-helix, first β-
strand and the loop between them interacts with SUMO protein, and mutations in 
this region significantly decrease the efficiency in the transfer of SUMO-1 from 
E1 to E2, but they will not affect substrate recognition or transfer of SUMO-1 from 
E2 to the target protein (30). 
 
I B.2.   E3 ligases 
For the final ligation step in the SUMO conjugation pathway, the Ubc9-
substrate interaction can also be facilitated by SUMO E3 ligases in a substrate-
specific manner. These proteins meet the definition of an E3 in that they can bind 
both the E2 and substrate, and also promote transfer of SUMO from the E2 to 
the substrate in vitro (22). Three different general types of SUMO E3 ligases 
have been described. The first E3 group is the protein inhibitor of activated STAT 
(PIAS) family of proteins, which mediate the sumoylation of c-jun, p53, etc. 
These E3 proteins share a common RING domain and bind directly to the Ubc9 
E2 enzyme and some SUMO protein targets. The RING finger motif is required 
for the E3 activity of PIAS proteins, and has also been identified in some of the 
ubiquitin E3 ligases (32). A second type of SUMO E3 protein is RAN binding 
protein 2 (RanBP2), a component of the nuclear pore complex (33). The 
functional E3 domain of RanBP2 is the internal repeat (IR) domain and shares no 
sequence similarity with any ubiquitin E3 proteins. RanBP2 promotes 
sumoylation of several proteins, including Histone deacetylase 4(HDAC4), Sp100, 
and RanGAP1. The final E3 protein type is polycomb 2 protein (Pc2), a member 
of Poly-comb protein family that stimulates sumoylation of the transcriptional 
corepressor, C-terminal Binding Protein (CtBP). Pc2 has no obvious sequence 
similarity to any other known E3s, and its E3 function depends on a C-terminal 
substrate binding domain and an N-terminal portion containing the 
chromodomain (34).  
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I B.3.   RanGAP1 
RanGAP1, a Ran GTPase-activating protein that plays a critical role in 
nuclear transport, was the first identified substrate for SUMO modification (35,36). 
Unsumoylated RanGAP1 localizes predominantly in the cytoplasm, and SUMO 
conjugation directs RanGAP1 to the cytoplasmic fibers of the NPC (35,37) in the 
interphase and mitotic spindles during mitosis. SUMO modification promotes 
association of RanGAP1 with the NPC by an interaction with RanBP2/Nup358 
(38). Meanwhile RanBP2 also colocalizes with RanGAP1 on spindles, and this 
two protein interaction may be related to mitotic targeting of RanGAP1 to the 
spindles. Additionally, RanGAP1 can also be phosphorylated during mitosis, but 
phosphorylation will not affect SUMO1 modification or association with RanBP2 
(39).   
 
I C.      Regulation of SUMO process 
The sumoylation process can itself be regulated in a more global way or in a 
substrate-specific manner. H2O2 inactivates Ubc9 and causes a global decrease 
in sumoylation levels (40). Conversely, many cellular stresses, including heat 
shock, cause global increases in sumoylation (41). MAPK pathways can promote 
de-sumoylation or sumoylation under different circumstances (22). Meanwhile, 
other post-translational modifications can also regulate the SUMO modification of 
a protein. For example, phosphorylation negatively regulates the sumoylation of 
several substrate proteins, including c-Jun, PML and P53 (42), but 
phosphorylation of some proteins, such as HSF1, can also stimulate their 
sumoylation (43,44).  
 
II.         PcG 
The Polycomb (PcG) gene was discovered as a mutation inducing a posterior 
transformation phenotype in Drosophila. Following research showed that Polycomb 
is a general repressor of homeotic genes, while trithorax group (TrxG) genes were 
shown to counteract PcG-mediated repression of homeotic genes (45).  
 
II A.     PcG complexes 
PcG proteins have been categorized into two families on the basis of their 
physical associations in various multiprotein complexes named as Polycomb 
repressor complexes (PRCs)- PRC1 and PRC2. PRC1 were first isolated from 
Drosophila embryos. It is about 2 MDa in size and consists of PcG proteins PC, PH, 
PSC and SCM. It is also associated with more than 30 other polypeptides, including 
several TBP-associated factors (TAF). PRC1 is primarily responsible for the 
maintenance of repression of gene expression (46-49), meanwhile PRC2 initiates 
repression. Transcription can be repressed by establishing a chromatin structure 
that blocks access of the transcription machinery directly, or indirectly, by inhibiting 
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chromatin remodeling that might be required for access. For example, the isolated 
core PRC1 complex, containing PC, PH, PSC and dRING1, is sufficient to inhibit 
chromatin remodeling by the SWI/SNF complex in vitro (50), and this complex can  
also induce in vitro compaction of polynucleosomal chromatin templates (51). The 
presence of TAFs in the PRC1 complex indicates the repression may also relate to 
inhibit the assembly or function of the transcription machinery. Additionally, the 
PRC1 complex also could promote gene silencing by possessing H2A-K119 
ubiquitin E3 ligase activity (52).  
The function of PRC2 is recognized as the ‘code of silence’-to initiate 
repression (50,53-55). PRC2 is about 600 kDa, in addition to ESC and E (Z), this 
complex also contains the SU(Z)12 and  associates with the histone deacetylase 
RPD3. The E(z) could methylate histone H3 at lysine 27 (H3-K27) both in vivo and 
in vitro. Because many Polycomb Response Elements (PREs) and other PcG-
silenced regions are associated with methylation of H3-K27, it has been suggested 
that this methylation mark is essential for PcG-mediated silencing. In fact, H3-K27 
methylated histones interact specifically with the chromodomain of Polycomb (Pc), a 
member of PRC1, and the lack of H3-K27 methylation caused by the disruption of 
the PRC2 complex is associated with a loss of Pc binding and derepression 
(46,47,49). Thus, PRC2 could help to target PRC1 to specific genomic loci by 
making the H3-K27 methylated mark.  
 
II B.     Mel-18 
Mel-18 is a member of the polycomb group of proteins that play a vital role in 
development and differentiation by controlling patterns of gene expression. Mel-18 
knockout mice shows severe combined immunodeficiency, growth retardation, and 
skeletal malformations (56). It has also been suggested Mel-18 could be a tumor 
suppressor: Mel-18 expression is decreased in human breast cancer cells (57). 
Additionally, inhibition of Mel-18 expression enabled immortal NIH 3T3 to cells form 
tumors in nude mice (58). Mel-18 anti-tumor activity is related with negative 
regulations of cell cycle progression by several ways: (a) Mel-18 can negatively 
regulate the activation of Cyclin-dependent kinases (CDK) by binding the c-Myc 
promoter, repressing its expression and then inhibiting c-myc/cdc25a cascade (59); 
(b) Bmi-1, another PcG protein, is an oncogene protein, and Mel-18–mediated 
repression of Bmi-1 is also associated with down regulation of c-myc, which will bind 
on the Bmi-1 promoter and promote its activities (60); (c) Direct Mei-18 interactions 
with cyclin D2 promote the inhibition of cyclin D2 activity (61); (d) Mel-18 could 
induce the inhibition of phosphatidylinositol 3-kinase/Akt signaling pathway, which is 
required for cytoplasm localization of p27(Kip1) and then activation of Cdk4 and 
Cdk2 activities (62).  
Mel-18 contains a conserved Really Interesting New Gene (RING) domain 
at the NH2 terminus. RING finger domain is a type of zinc finger containing a 
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Cys3HisCys4 amino acid motif and this domain plays a very important role in 
Mel-18 functions: (a) the formation of Mel-18 homodimers requires the N-terminal 
domain containing RING finger motifs (63); (b) the RING finger domain shows 
DNA binding activities such as binding the c-myc promoter (59); (c) Mel-18 RING 
domain also participates in the Mel-18 recognition of the nucleosome (64).   
 
II C.     Bmi-1 
Bmi-1 was first cloned as a c-myc cooperating oncogene in murine lymphomas 
(65,66), and subsequently shown to be a transcriptional repressor belonging to the 
PcG class of proteins (67). Previous studies have identified several ways in which 
Bmi-1 mediates its effects on cell proliferation, including inhibiting expression of the 
Ink4A/ARF locus (68), modulating the p21-Rb pathway (69), and inducing 
telomerase activity (70). In addition to its function as an oncogene, Bmi-1 also plays 
important roles in determination of cell fate and stem cell renewal of the neural, 
hematopoietic, and other cell lineages (67,71-77) 
Bmi-1 contains a conserved RING finger domain at the NH2 terminus, which 
plays a very important role in Bmi-1 function. RING finger domain is required for the 
subnuclear localization of Bmi-1 to the nuclear rim and is associated with its ability to 
transform (78). Deletion analysis of the Bmi-1 protein indicates that this domain, as 
well as another conserved domain, are also required to induce telomerase activity 
and immortalize human Mammary Epithelial Cells (70). A previous study also 
showed the regulation of TH2 cell differentiation by Bmi-1 is in a RING finger-
dependent manner by controlling GATA binding protein 3 (GATA3) stability (79). An 
intact Bmi-1 RING finger is also necessary but not sufficient for dinG protein binding 
(80). Meanwhile, Bmi-1 has been found to be predominantly localized to the nucleus, 
which is mediated by a nuclear localization sequence (NLS) located in the C-
terminal region of this protein (70,78) .  
 
II D.     Distinct and overlapping functions for Mel-18 and Bmi-1 
II D.1.  Similar structures, synergetic and overlapping functions 
Bmi-1 and Mel-18, both belonging to the PRC1 complex, exhibit high 
homology to each other. They have 65% amino acid identity and also contain the 
similar structures: a RING finger domain in the N terminus, a helix-turn-helix 
domain in the middle and proline-rich sequences in the C-terminus.  
Animal studies showed Bmi-1−/− and Mel-18−/− mice have similar 
phenotypes, such as severe combined immunodeficiency, growth retardation, 
and skeletal malformations (67,81). Mice with a double knockout of these two 
proteins display a more serious exacerbation of the single Bmi-1 or Mel-18 
protein knockout phenotype (82). 
Bmi-1 and Mel-18 also play significant roles in the regulation of lymphocyte 
differentiation: (a) For B cell development, Bmi-1 is very important (67); 
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meanwhile, without Mel-18, B cell maturation is also arrested between the pro- 
and pre-B cell stages (83). Meanwhile, in mature resting B cells, Mel-18 inhibits B 
cell receptor-induced proliferation by transcriptional repression of c-myc protein 
and then down regulation of c-myc/cdc25a cascade (59); (b) In thymocyte 
development, Mel-18 is indispensable for the expansion of adult and fetal early T 
progenitors by regulation of  Hes-1 gene expression (84), Bmi-1 is also important 
for thymocyte development at an immature stage (85); (c) Both of Bmi-1 and Mel-
18 regulate TH2 cell differentiation by controlling GATA3 (79); (d) Severe combined 
immunodeficiency seen in Mel-18 and Bmi-1 mutants is associated with  
impairment in the IL-7–dependent proliferation of lymphocyte precursors (83). 
 
II D.2.  Complicated roles in tumor cell growth 
Bmi-1 was first cloned as a c-myc cooperating oncogene in murine lymphoma 
cells (65,66). Previous studies have identified several ways in which Bmi-1 mediates 
its effects on promotion of cell proliferation (68,85) and inducing telomerase activity 
(70). Unlike Bmi-1, the highly homologous Mel-18 was shown to have tumor-
suppressive effects and also down regulate cell progression by several ways (59-
62).  
Recent studies suggest that Bmi-1 and Mel-18 may have overlapping 
functions in cancer cell growth (56): both Bmi-1 and Mel-18 can increase the 
proliferation of rodent fibroblasts (78,86); knockdown of either Bmi-1 or Mel-18 
results in the inhibition of proliferation in human medulloblastoma DAOY cells, 
but not in normal human WI38 fibroblasts. Finally, gene expression analysis 
demonstrated Bmi-1 and Mel-18 share many target proteins in a number of 
cancer-relevant pathways (56). 
 
III. Heat Shock Factors (HSFs) 
HSFs proteins are characterized by binding to the heat shock element 
(HSE), nGAAn, on Heat shock protein (Hsp) genes, which are typically silent at 
normal growth temperatures but are expressed at extremely high levels at 
elevated temperatures or other kinds of stress. All HSFs share structurally 
conserved domains, including the N-terminal looped helix-turn-helix DNA-binding 
domain (DBD). HSF1 is activated and binds to HSE by heat shock and other 
forms of stress, whereas HSF2 is activated during hemin-induced differentiation 
of human K562 erythroleukemia cells, but it has also shown that HSF2, in 
common with HSF1, participates in the activation of the hsp70 promoter by heat 
shock (9). The regulation of HSF2 has been linked to certain development- and 
differentiation-related processes, such as gametogenesis and pre- and 
postimplantation development of mouse embryos (10-14). 
Previous works in our lab showed that HSF2 plays a crucial role in 
bookmarking the hsp70 promoter during mitosis. Most sequence-specific DNA-
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binding proteins are released, and chromatin undergoes condensation (15,16) 
during mitosis, however, the promoters of some genes still remain accessible 
(15,17-19), which is referred to as “bookmarking” . HSF2 mediates bookmarking 
of the stress-inducible hsp70 gene by binding to heat shock elements (HSEs) in 
its promoter, recruiting the phosphatase PP2A, and interacting with the CAP-G 
subunit of the condensin complex to promote dephosphorylation of the nearby 
condensin complexes, thereby preventing compaction of this region of 
chromosomal DNA in mitotic cells (20).  
 
This study also found that sumoylation of HSF2 protein is upregulated in 
mitotic cells compared with asynchronous cells and is crucial for the ability of 
HSF2 to interact with the CAP-G, indicating that this modification could be a 
regulator of the HSF2 bookmarking function (Figure 1.3). However, how the 
increase in HSF2 sumoylation during mitosis is regulated was not known. In 
order to further understanding of the regulation and function of HSF2 in cells, our 
former labmate Dr. Goodson performed a yeast two-hybrid screen using the 
HSF2 protein as a bait. One of the HSF2-interacting clones obtained from this 
screen represented a region of the polycomb group protein Mel-18, then the 
following characterization and function studies of this interaction were the focus of 
my doctoral work. As described above in the introduction, previous studies showed 
that RING finger proteins could function as an E3 protein to stimulate sumoylation of 
specific target proteins, so we sought to determine whether this RING finger protein 
Mel-18 may play a role in regulating sumoylation of HSF2. Here my research shows 
that Mel-18 inhibits HSF2 sumoylation by interacting with both HSF2 and ubc9, and 
inhibiting the ability of ubc9 to transfer the SUMO protein to HSF2. This study also 
suggests that Mel-18 regulates the sumoylation of other cellular proteins, but the 
identities of these other proteins were unknown. RanGAP1 is a very important 
cellular SUMO substrate protein, in fact the first identified substrate for SUMO-1 
conjugation, however the regulation of its sumoylation was also unclear. Therefore, 
in the following study we sought to determine whether the sumoylation of RanGAP1 
is also regulated by Mel-18, and if so whether this involves interaction between 
these two proteins. My study suggests that Mel-18 interacts with RanGAP1 and 
inhibits its sumoylation, and that these activities do not require the RING domain 
of Mel-18. The results also show that RanGAP1 sumoylation is decreased during 
mitosis, and that this is associated with increased interaction between RanGAP1 
and Mel-18. Previous studies showed little evidence of anti-SUMO E3 proteins, 
but taken together, my doctoral work suggests that Mel-18 actually functions as a 
novel anti-SUMO E3 protein, interacting both with HSF2/RanGAP1 and the 
SUMO E2 Ubc9 but acting to inhibit Ubc9 activity to decrease sumoylation of 
target proteins and also provide an explanation for how mitotic HSF2/RanGAP1 
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sumoylation is regulated. This finding also gives a clue for a future study direction 
in Mel-18 as a tumor suppressor: the anti-SUMO E3 function. 
Additionally, searching in SNP database, we identify a single-nucleotide 
polymorphism in human Bmi-1 that changes a cysteine residue within its RING 
domain, cysteine 18, to a tyrosine.  Because its RING finger has been found to 
be related with its subnuclear localization, therefore, we hypothesized that this 
C18Y polymorphism could affect its pattern of localization within the cell.  
However results of the fluorescence microscopy experiment did not indicate a 
difference in localization, but they did show that a less intensity of the signal from 
the C18Y GFP-Bmi-1. So we hypothesized that this may be associated with a 
decrease in levels of C18Y Bmi-1 protein. Consistent with this hypothesis we find 
that the low levels of this form of Bmi-1 are due to its destruction by the ubiquitin-
proteasome system. This is the first example of a polymorphism in human Bmi-1 
that reduces levels of this important protein.  
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Figure 1.1 the SUMO conjugation pathway. (Taken from Ref. 22)  
 
SUMO protease Ulp1 cleaves SUMO into its mature form. Then in the activation 
step, SUMO is conjugated to the Uba2 subunit of the E1- activating heterodimer 
Aos1/Uba2 in an ATP-dependent manner. In the following conjugation step, 
SUMO is transferred to the E2-conjugating enzyme Ubc9. And in the final step, 
SUMO is transferred and ligated to substrate proteins by forming a bond between 
the terminal glycine on SUMO and the lysine in the target protein. SUMO groups 
are removed by SUMO-specific proteases, such as specific peptidase, SENPs.
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Fig 1.2 Ubc9 ribbon diagram and secondary structure assignment (Taken 
from Ref. 31) 
 
Ubc9 structure is similar to other ubiquitin E2 family members: an N-terminal α 
helix, five- to seven-stranded β sheet, the loop containing the catalytic cysteine 
(cys 93), and three C-terminal α helices. 
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 Figure 1.3 Model of events leading to ‘bookmarking’ of the hsp70 promoter 
during mitosis. (Taken from Ref. 21) 
 
HSF2 mediates bookmarking of the stress-inducible hsp70 gene. HSF2 binds to 
heat shock elements (HSEs) in its promoter after sumoylation and trimization, 
recruits the phosphatase PP2A, and interacts with the CAP-G subunit of the 
condensin complex to promote dephosphorylation of the nearby condensin 
complexes, thereby prevents compaction of this region of chromosomal DNA in 
mitotic cells. 
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CHAPTER TWO:  
MEL-18 INTERACTS WITH HSF2 AND THE SUMO E2 UBC9 TO INHIBIT 
HSF2  
 
BACKGROUND 
Covalent attachment of Small Ubiquitin-like Modifier (SUMO) proteins to 
lysine residues in target proteins, or sumoylation, is an important regulator of 
protein functional properties (23,40,87-90). SUMO proteins are covalently 
attached to target lysine residues by the SUMO E2 enzyme, Ubc9, and these 
substrate lysines are typically found within the consensus sequence ΨKXE (Ψ 
represents hydrophobic amino acids) (42,91-93). SUMO E3 proteins have been 
identified that enhance the efficiency of sumoylation by interacting with both 
Ubc9 (SUMO E2) and the target protein, thereby acting as bridging factors to 
increase the rate of the sumoylation reaction (94,95).  
Previous studies in our and another laboratory revealed that a DNA-binding 
protein called heat shock factor 2 (HSF2) is a target of sumoylation in vivo 
(96,97). Our prior work indicated that one of the functions of HSF2 is to bind 
during mitosis to heat shock elements (HSEs) in the promoters of the hsp70 and 
other heat shock protein genes to mediate an epigenetic function called gene 
bookmarking on these promoters (20,21). The results of this study also indicated 
that sumoylation of HSF2 is up-regulated during mitosis and is important for this 
factor’s interaction with a subunit of the condensin complex during the 
bookmarking process, suggesting that this modification is involved in regulating 
HSF2 bookmarking function (20). However, how the increase in HSF2 
sumoylation during mitosis is regulated was not known. 
Mel-18 is a member of the polycomb group of proteins that play a vital role 
in development and differentiation by controlling patterns of gene expression (98-
102). One important development with respect to the functional roles of polycomb 
proteins was the discovery that at least one of them, Pc2 (Cbx4), functions as a 
SUMO E3 to stimulate the sumoylation of specific target proteins (102,103).  
The results presented in this chapter now identify the existence of an 
interaction between HSF2 and the polycomb group protein Mel-18, and suggest 
that cell-cycle-dependent interaction between Mel-18 and HSF2 functions as a 
mechanism for the previously observed up-regulation of HSF2 sumoylation 
during mitosis. The results also support the intriguing hypothesis that Mel-18, in 
contrast to the polycomb protein Pc2/Cbx4 whose SUMO E3 activity stimulates 
sumoylation of certain proteins, actually functions like an anti-SUMO E3 protein, 
interacting both with HSF2 and the SUMO E2 Ubc9, but acting to inhibit Ubc9 
activity and thereby decrease sumoylation of a target protein, in this case that of 
HSF2. 
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MATERIALS AND METHODS 
Cell culture: Hela-ATCC cells and HEK 293T cells were grown at 37°C in 
DMEM supplemented with 10% FBS.  
Generation of antibodies against Mel-18: Affinity purified goat polyclonal 
antibody to Mel-18 was prepared by Bethyl Laboratories (Montgomery, TX) and 
was raised against the synthetic peptide STSRGRKMTVNGAPVPPLT, which 
corresponds to the C-terminal sequence of the human Mel-18 polypeptide.  
Plasmid construction: pEGFP-Mel-18 plasmid was generated by using 
PCR to amplify from the plasmid pSG5-Mel-18 cDNA a coding fragment of Mel-
18 having KpnI and BamHI sites at the ends using the following primers: 5′-GCG 
GGT ACC TCC ATG CAT CGG ACT ACA CGG-3′ and 5′-CGC GGA TCC AGA 
GGG TCC CTT TCC TCA AGG-3′. PCR amplifications were performed using the 
following program: 95°C for 5 min, 30× (95°C for 1 min, 59°C for 1 min, 72°C for 
2 min), 72°C for 5 min . This PCR product was then cloned into pEGFP-C1 
vector (Clontech, Mountain View, CA) at the KpnI and BamHI sites to form the 
pEGFP-Mel-18 plasmid. This plasmid was confirmed by DNA sequencing.  
GST-pulldown assays: For in vitro binding between Mel-18 and HSF2, 
GST-HSF2 was expressed in E. coli from the pGEX-HSF2 plasmid and GST was 
expressed from the pGEX plasmid, and then bacteria were resuspend and 
sonicated 5 times in 1PBS plus 1.5% sarkosyl, 1mM PMSF and 1 protease 
inhibitor (1PI), finally lysates of these bacteria were incubated with glutathione-
agarose beads for about 2 hours at 4°C with rotation followed by washes. The 
GST and GST-HSF2 bound to beads were then incubated with [35S]methionine-
labeled Mel-18 created by coupled in vitro transcription and translation system in 
rabbit reticulocyte lysates (TNT, Promega, Madison, WI) overnight at 4°C with 
rotation in Buffer D (20 mM HEPES, (pH 7.9), 0.2 mM EDTA, 0.1 M KCl, and 
20% v/v glycerol), in a total volume of 650 μl. After washing four times with Buffer 
D, the amount of [35S]-methionine-labeled Mel-18 bound to the GST or GST-
HSF2 was determined by boiling the beads in SDS-PAGE buffer followed by 
SDS-PAGE and autoradiography. For in vitro binding between Mel-18 and Ubc9, 
similar amounts of purified GST or GST-Ubc9 were bound to glutathione–
agarose beads and then incubated with extracts of HeLa cells made using NP-40 
lysis buffer (1% NP-40, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM 
dithiothreitol, and complete protease inhibitor cocktail (Roche Applied Science, 
Indianapolis, IN). After washing six times with NP-40 buffer, bound protein 
complexes were separated by SDS–PAGE and analyzed by Western blot using 
the anti-Mel-18 goat polyclonal antibodies (Bethyl) raised as described above.  
Immunoprecipitation analysis: For co-immunoprecipitation experiments, 
asynchronous HeLa cells or HeLa cells blocked in mitosis (treated with 400 ng/ml 
nocodazole for 16 hours) were extracted on ice with NP-40 lysis buffer (1% NP-
40, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM dithiothreitol, and complete 
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protease inhibitor cocktail (Roche Applied Science)) for 20 minutes. Lysates were 
then cleared by centrifugation at 16,438 g for 10 minutes at 4°C. Supernatants 
were precleared by incubation with rabbit (control) IgG and protein G-sepharose 
beads for 2 hours at 4°C with gentle rotation. Precleared extracts were then 
incubated with primary rabbit polyclonal HSF2 antibody or control IgG and 50% 
slurry of protein G-sepharose for 4 hours at 4°C with rotation. After washing 
beads 6 times for 5 minutes each at 4°C with NP-40 buffer, bound proteins were 
released by boiling in SDS PAGE sample dye and analyzed by Western blot 
using the anti-Mel-18 goat polyclonal antibody (Bethyl) or anti-HSF2 goat 
polyclonal antibody (Bethyl). For immunoprecipitation analysis of HSF2 
sumoylation, HEK 293T cells were transfected with pEGFP-Mel-18 or pEGFP-C1 
along with myc-sumo-1 expression plasmid using Effectene transfection reagent 
according to the manufacturer’s instructions (Qiagen, Valencia, CA). After 48 
hours cell extracts were prepared in NP-40 Buffer (50 mM Tris–HCl, (pH 8.0), 
150 mM NaCl, 1% Nonidet P-40, 1 mM dithiothreitol, and complete protease 
inhibitor cocktail (Roche Applied Science), 10 mM N-ethylmaleimide) before 
adding HSF2 polyclonal antibodies or non-specific IgG to proceed as described 
above, followed by Western blot assay using anti-myc monoclonal antibody 
(Invitrogen, Carlsbad, CA). For immunoprecipitation analysis of HSF1 
sumoylation, HEK 293T cells were transient transfected with pEGFP-Mel-
18/pEGFP-C1 and myc-sumo-1 using Effectene transfection reagent according 
to the manufacturer’s instructions (Qiagen). After 48 hours, the cells were heat-
treated at 42°C for 1 hour and then harvested. Cell extracts were prepared in NP-
40 Buffer before adding HSF1 polyclonal antibodies to proceed as above, 
followed by Western blot using anti-myc monoclonal antibody (Invitrogen). This 
assay was normalized with cell number. 
In vitro sumoylation assay: Full length HSF2 was in vitro translated in a 
rabbit reticulocyte lysates using the TNT-coupled transcription-translation system 
(Promega) with 35S methionine at 30º C for 2 h. Then in vitro translated product 
was incubated with Ubc9 and GST-SUMO-1 in reaction buffer (50 mM HEPES, 
pH 7.4, 100 mM NaCl, 10 mM MgCl2, 2mM ATP, 1 mM dithiothreitol) at 30°C for 
1 h (44) in the presence or absence of purified recombinant GST-Mel-18 or GST. 
Samples were resolved out on SDS-PAGE gels. 
Mel-18 RNAi: Mel-18 short-hairpin RNA (shRNA) was designed by 
Oligoengine (Seattle, Washington) and cloned in the pSUPER-EGFP vector at 
the BglII and HindIII sites. The sequence of the shRNA used was as follows: 5′ 
CGACGCCACCACUAUCGUG 3′. The pSuper-Scramble plasmid 
(GATCCCCTTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGA
GAATTTTTA), generously provided by Doug Andres (University of Kentucky), 
was used as a control for this experiment. The pSUPER-shRNA-Mel-18 and 
pSUPER-scrambled were transiently transfected into HeLa cells using Jet-PEI 
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reagent according to the manufacturer’s instructions (polyplus-transfection, New 
York, NY). After 48 hours, the cells were harvested. Cell extracts were prepared 
in NP-40 Lysis Buffer before adding HSF2 polyclonal antibodies to proceed as 
above, followed by Western blot using anti-myc monoclonal antibody (Invitrogen). 
 
RESULTS 
In order to further understand the regulation and function of HSF2 in cells, 
our former labmate Dr. Goodson performed a yeast two-hybrid screen using the 
HSF2 protein as a bait. One of the HSF2-interacting clones obtained from this 
screen represented a region of the polycomb group protein Mel-18. This clone 
did not interact with a bait containing HSF1, a protein with high sequence-
relatedness to HSF2, indicating the specificity of this interaction. The location of 
the region in Mel-18 found in the interacting yeast two-hybrid clone, which 
comprises amino acids 144-271 of the protein, is shown in the schematic in 
Figure 2.1A. Then my doctoral work focuses on the following characterization 
and function analysis for this interaction.  
As an independent test of the interaction between HSF2 and Mel-18, and to 
determine whether the interaction is direct, an in vitro binding experiment was 
performed in which 35S-labelled in vitro translated Mel-18 was incubated with 
GST-HSF2 or GST-HSF1 bound to glutathione-agarose beads. The results of 
this experiment demonstrate the ability of HSF2 to interact with Mel-18, and 
indicate that the interaction is direct (Fig 2.1B). 
To determine whether endogenous HSF2 and Mel-18 proteins interact, 
immunoprecipitation analysis was performed. Because our previous studies 
revealed that HSF2 function is regulated in a mitosis-dependent manner (20), 
this analysis was performed using extracts of asynchronous cells as well as 
those of cells blocked in mitosis by nocodazole treatment. The results of this 
experiment indicate that endogenous HSF2 and Mel-18 proteins do associate, 
and that lower levels of HSF2-Mel-18 complex are observed in extracts of mitotic 
cells compared to those of asynchronous cells (Fig 2.2). 
As described above in the Introduction, previous studies showed that the 
polycomb protein Pc2/Cbx4 functions as an E3 protein to stimulate sumoylation 
of specific target proteins (103,104). Based on these findings, we sought to 
determine whether this polycomb protein Mel-18 may play a role in regulating 
sumoylation of HSF2. Specifically, our previous finding of increased sumoylation 
of HSF2 during mitosis (20), coupled with our new results in Figure 2.2 indicating 
that interaction between HSF2 and Mel-18 is decreased during mitosis, 
suggested the intriguing hypothesis that Mel-18 may actually function as a 
negative regulator of HSF2 sumoylation. This would be in contrast to the 
sumoylation-stimulatory function of the polycomb protein Pc2/Cbx4. As a first test 
of this hypothesis, we determined whether adding purified recombinant GST-Mel-
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18 to an in vitro sumoylation assay would affect the SUMO modification of HSF2 
`in this system. As shown in Figure 2.3, addition of purified GST-Mel-18 is 
associated with decreased sumoylation of HSF2 in the in vitro modification assay. 
Next, we wanted to test whether Mel-18 can inhibit the sumoylation of HSF2 
expressed in cells. To test this, GFP-Mel-18 or GFP expression constructs, along 
with myc-SUMO-1 expression plasmid, were transfected into cells and then 
extracts of the cells were subjected to immunoprecipitation with anti-HSF2 
antibodies or non-specific IgG (negative control), followed by anti-myc Western 
blot to detect the sumoylated forms of the HSF2 protein. The results of this 
experiment, shown in Figure 2.4A, indicate that expression of GFP-Mel-18, but 
not GFP, is associated with decreased HSF2 sumoylation. To probe the 
specificity of this effect of GFP-Mel-18 in inhibiting HSF2 sumoylation, we 
performed a similar experiment to analyze the related HSF1 protein, which we 
and others have previously shown to be sumoylated in response to stress (25,26). 
The results show that HSF1 sumoylation is not significantly affected by 
expression of GFP-Mel-18 (Figure 2.4B), indicating the selectivity of the inhibitory 
effect of Mel-18 overexpression on sumoylation of HSF2. 
As a reverse, complementary approach for testing this hypothesis that Mel-
18 may be a negative regulator of HSF2 sumoylation, we determined the effect of 
reducing cellular levels of Mel-18, using the RNAi methodology, on HSF2 
sumoylation. According to our hypothesis and the results in Figure 2.3 and 2.4, 
we predicted that knockdown of Mel-18 should result in an increase in 
sumoylation of HSF2. To test this, cells were transfected with Mel-18 shRNA or 
scrambled shRNA, along with myc-SUMO-1 expression plasmid, and then 
extracts of the cells were subjected to immunoprecipitation with anti-HSF2 
antibodies or non-specific IgG (negative control), followed by anti-myc Western 
blot to detect the sumoylated forms of HSF2. As shown in Figure 2.5, the results 
of this experiment indicate that, consistent with our hypothesis, a reduction in 
Mel-18 protein levels is associated with an increase in HSF2 sumoylation. These 
results, together with those shown in Figure 2.3 and 2.4 above, support the 
hypothesis that Mel-18 functions as an inhibitor of HSF2 sumoylation. 
Next, we sought to probe the underlying mechanism by which Mel-18 
inhibits the sumoylation of HSF2. A previous study showed that the polycomb 
protein Pc2 mediates its effects on sumoylation of its target proteins by 
interacting with Ubc9, the SUMO E2 enzyme (104). Based on this finding, we 
hypothesized that Mel-18 may also interact with Ubc9 as part of its mechanism 
for inhibiting HSF2 sumoylation. To test this hypothesis, we performed an in vitro 
binding experiment to determine whether Mel-18 protein present in whole cell 
extracts can interact with purified recombinant GST-Ubc9 bound to glutathione-
agarose beads. In this experiment, after incubating the GST-Ubc9 or GST bound 
to glutathione-agarose with HeLa cell extracts and washing the beads to remove 
16 
unbound proteins, the amount of Mel-18 bound was determined by boiling the 
beads in SDS-PAGE buffer followed by Western blot using anti-Mel-18 
antibodies. The results of this experiment indicate that purified recombinant Ubc9 
is able to interact with Mel-18 present in cell extracts (Figure 2.6A). 
To test for interaction between endogenous Mel-18 and Ubc9 proteins, we 
subjected cell extracts to immunoprecipitation using Mel-18 antibodies, followed 
by Western blot of the immunoprecipitates using Ubc9 antibodies. The results, 
shown in Figure 2.6B, indicate that endogenous Mel-18 and Ubc9 do interact. 
The results also suggest that there is more complex between Mel-18 and the 
form of Ubc9 that is covalently charged with SUMO (39 kDa form), relative to the 
non-SUMO-carrying form of Ubc9 (18 kDa form). 
Based on this finding of interaction between Mel-18 and Ubc9, we 
envisioned a mechanism in which Mel-18 bound to HSF2 inhibits its sumoylation 
by binding to and inhibiting the activity of Ubc9 enzymes that approach HSF2. 
One way of inhibiting Ubc9 activity would be to block its ability to transfer the 
SUMO group from its active site to the target protein. Therefore, as a means for 
testing this proposed mechanism, we determined whether increasing the level of 
Mel-18 in cells results in increased amounts of the form of Ubc9 that has SUMO 
remaining covalently bound to it. GFP-Mel-18 or GFP alone were expressed in 
HEK 293 cells by transfection and then extracts of the transfected cells were 
subjected to Western blot with anti-Ubc9 antibodies, which will detect both the 18 
kDA non-SUMO-containing form of Ubc9 and the 39 kDA SUMO-containing form 
of Ubc9. The results of this experiment, shown in Figure 2.6C, indicate that 
expression of the GFP-Mel-18 results in increased levels of the SUMO-
containing form of Ubc9 compared to cells expressing the GFP alone construct. 
This result supports the hypothesis that Mel-18 inhibits Ubc9 activity by 
decreasing its ability to transfer SUMO groups to target proteins. 
Based on the results shown in Figure 2.6 indicating that Mel-18 interacts with 
Ubc9 and may inhibit its ability to attach SUMO groups to proteins, we 
hypothesized that Mel-18 may inhibit the sumoylation of other proteins in addition 
to HSF2, perhaps even acting to down-regulate cellular sumoylation globally. To 
test this hypothesis, extracts of HEK 293 cells transfected with GFP-Mel-18 or 
GFP expression constructs along with the myc-SUMO-1 expression plasmid from 
the experiment shown in Figure 2.4 were subjected to Western blot using anti-
myc and anti-SUMO-1 antibodies to detect sumoylated forms of cellular proteins. 
Consistent with this hypothesis, the results of this analysis indicate that increased 
expression of Mel-18 is associated with a detectable decrease in conjugation of 
SUMO-1 to cellular proteins (Figure 2.7).  
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CONCLUSION 
The results presented in this chapter support the hypothesis that Mel-18 
bound to HSF2 inhibits its sumoylation by binding to and inhibiting the activity of 
SUMO E2 (Ubc9) enzymes in the vicinity of the HSF2 protein. Further, our 
results showing that the interaction between HSF2 and Mel-18 is decreased 
during mitosis would provide a mechanism to explain the previously observed 
finding that HSF2 sumoylation is increased during this stage of the cell cycle (20). 
The results described in this paper also suggest that Mel-18 actually 
functions like an anti-SUMO E3 protein, because like a traditional SUMO E3 
protein it interacts both with the SUMO E2 enzyme Ubc9 and a sumoylation 
substrate protein (HSF2), but instead of stimulating SUMO modification of HSF2 
it inhibits it. This is in contrast to the sumoylation-stimulating activities of another 
polycomb protein, Pc2, a traditional SUMO E3, indicating that members of the 
polycomb group of proteins are involved in both the positive and negative 
regulation of protein sumoylation through their interactions with Ubc9 and 
substrate proteins. The results also indicate that Mel-18 is able to detectably 
inhibit conjugation of SUMO-1 to proteins, suggesting that Mel-18 likely inhibits 
the sumoylation of other proteins in addition to HSF2, perhaps even acting to 
down-regulate sumoylation in cells globally. 
Future studies investigating whether additional polycomb proteins act as 
positive or negative regulators of the sumoylation of proteins in cells, and 
identifying other SUMO substrate proteins whose modification is regulated by 
these polycomb proteins, would likely provide important insights into both the 
regulation of protein sumoylation and the mechanisms by which polycomb 
proteins mediate their important biological functions. 
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Figure 2.1 HSF2 interacts with Mel-18 
(A) Schematic depicting the location within Mel-18 of the segment (amino acids 
144-271) identified as an HSF2-interacting region in the yeast two-hybrid assay. 
(B) 35S-labeled in vitro translated Mel-18 was incubated with GSTHSF2, GST-
HSF1 that were bound to glutathione-agarose beads. After washing, the amount 
of bound 35S-labeled Mel-18 was determined by SDS-PAGE and 
autoradiography (upper panel). The amounts of GST-HSF2 and GST-HSF1 
bound to the beads were determined by performing anti-GST Western blot (lower 
panel). This figure is representative of this experiment performed minimally 3 
times. 
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Figure 2.2 Interaction between HSF2 and Mel-18 is decreased during 
mitosis 
Extracts of asynchronous or mitotic HeLa cells were immunoprecipitated using 
anti-HSF2 antibodies or non-specific IgG and the immunoprecipitates subjected 
to Western blot using anti-Mel-18 antibodies. The amounts of HSF2 in the Input 
and anti-HSF2 immunoprecipitate samples were measured by subjecting these 
samples to Western blot using goat polyclonal anti-HSF2 antibodies. This figure 
is representative of this experiment performed minimally 3 times. 
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Figure 2.3 Purified Mel-18 inhibits in vitro sumoylation of HSF2 
35S-labeled in vitro translated HSF2 was subjected to in vitro sumoylation in the 
absence of any additional purified proteins (lane 2), or in the presence of purified 
GST-Mel-18 (lane 3) or GST (lane 4). Samples were then analyzed by SDS-
PAGE and autoradiography (upper panel). The anti-GST Western blot (lower 
panel) shows the relative amounts of GST-Mel-18 or GST that were added to the 
reactions in lanes 3 and 4 of the upper panel, respectively. This figure is 
representative of this experiment performed minimally 3 times. 
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Figure 2.4 Mel-18 inhibits sumoylation of HSF2 in vivo 
(A) HEK 293 cells were transfected with GFP-Mel-18 or GFP expression 
constructs along with myc-SUMO-1 expression plasmid, and then extracts of the 
cells were subjected to immunoprecipitation with anti-HSF2 antibodies (rabbit 
polyclonal) or non-specific IgG (negative control), followed by anti-myc Western 
blot to detect the sumoylated forms of HSF2, and to Western blot using goat 
polyclonal HSF2 antibodies (Bethyl Inc.). The cell lysates were subjected to anti-
GFP Western blot to analyze expression levels of GFP-Mel-18 and GFP, and to 
anti-β-actin Western blot as a loading control. (B) A similar experiment to that 
described in panel A was performed, except that here the cells were subjected to 
a 42°C heat treatment for 60 minutes prior to harvesting them for 
immunoprecipitation analysis (to allow stress-induced HSF1 sumoylation) and 
that anti-HSF1 antibodies were used for the immunoprecipitation step, so that 
sumoylated forms of HSF1 would be detected by the subsequent anti-myc 
(detecting myc-SUMO-1) Western blot. This figure is representative of this 
experiment performed minimally 3 times. 
22 
 
 
 
Figure 2.5 Knockdown of Mel-18 protein levels is associated with increased 
HSF2 sumoylation  
HeLa cells were transfected with Mel-18 shRNA or scrambled shRNA along with 
the myc-SUMO-1 expression plasmid, and then extracts of the cells were 
subjected to immunoprecipitation with anti-HSF2 antibodies (rabbit polyclonal) or 
non-specific IgG (negative control), followed by anti-myc Western blot to detect 
the sumoylated forms of HSF2, and to Western blot using goat polyclonal HSF2 
antibodies (Bethyl Inc.). The cell lysates were subjected to anti-Mel-18 Western 
blot to confirm reduction of Mel-18 protein levels by Mel-18 shRNA treatment, 
and to anti-β-actin Western blot as a loading control. This figure is representative 
of this experiment performed 2 times. 
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Figure 2.6 Mel-18 interacts with the SUMO E2 enzyme, Ubc9 
(A) GST or GST-Ubc9 proteins bound to glutathione-agarose beads were 
incubated with extracts of HeLa cells, and then after washing the amount of 
bound Mel-18 was determined by Western blot using anti-Mel-18 antibodies. The 
anti-GST Western blot (lower panel) shows the relative amounts of GST-Ubc9 or 
GST that were used in the binding reactions, respectively. (B) Extracts of HeLa 
cells were subjected to immunoprecipitation using anti-Mel-18 antibodies, 
followed by Western blot of the immunoprecipitates using Ubc9 antibodies. (C) 
HEK 293 cells were transfected with the GFP or GFP-Mel-18 expression 
constructs, and then extracts of the transfected cells were subjected to Western 
blot assay using anti-Ubc9 antibodies to detect the non-SUMO-conjugated (18 
kDa) and SUMO-containing (39 kDa) forms of Ubc9. The cell lysates were also 
subjected to anti-β-actin Western blot as a loading control. This figure is 
representative of this experiment performed minimally 3 times. 
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Figure 2.7 Mel-18 inhibits general protein sumoylation in cells 
Extracts of HEK 293 cells transfected with GFP-Mel-18 or GFP expression 
constructs along with the myc-SUMO-1 expression plasmid from the experiment 
shown in Figure 2.4 were subjected to Western blot using anti-myc and anti-
SUMO-1 antibodies to detect sumoylated forms of cellular proteins, and to anti-β-
actin Western blot as a loading control. This figure is representative of this 
experiment performed minimally 3 times. 
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CHAPTER THREE:  
MEL-18 INTERACTS WITH RANGAP1 AND INHIBITS ITS SUMOYLATION  
 
BACKGROUND 
Covalent attachment of Small Ubiquitin-like Modifier (SUMO) proteins to 
lysine residues in target proteins, or sumoylation is an important regulator of 
protein functional properties (88-90,105-106). SUMO proteins are covalently 
attached to target lysine residues by the SUMO E2 enzyme, Ubc9, and these 
substrate lysines are typically found within the consensus sequence ΨKXE (Ψ 
represents hydrophobic amino acids) (42,91-93). 
SUMO E3 proteins have been identified that enhance the efficiency of 
sumoylation by interacting with both Ubc9 (SUMO E2) and the target protein, 
thereby acting as bridging factors to increase the rate of the sumoylation reaction 
(33,88,90,94,95,104,105,107). However, the results in the previous chapter 
revealed the surprising finding that a member of the polycomb group of proteins, 
called Mel-18, functions like an anti-SUMO E3 protein (108). In this study it was 
found that Mel-18 binds to and inhibits the sumoylation of a protein called HSF2 
by interacting with and inhibiting the activity of Ubc9 enzymes in the vicinity of 
HSF2. These results also indicated that Mel-18 may function to inhibit the 
sumoylation of other cellular proteins, but the identities of these other proteins 
were unknown. 
RanGAP1, a Ran GTPase-activating protein that plays a critical role in 
nuclear transport, was the first identified substrate for SUMO modification (37,38). 
The results presented in this chapter reveal that Mel-18 interacts with RanGAP1 
and inhibits its sumoylation, and that these effects do not require the RING 
domain of Mel-18. The results also show that RanGAP1 sumoylation decreases 
during mitosis and that this is correlated with increased interaction between 
RanGAP1 and Mel-18 during this stage of the cell cycle, which is the reverse of 
the regulatory relationship between Mel-18 and HSF2 sumoylation with respect 
to mitosis. These results strengthen support for the function of the polycomb 
protein Mel-18 as an anti-SUMO-E3 factor, and indicate that it is an important 
regulator of the sumoylation of a number of vital proteins in the cell. 
 
MATERIALS AND METHODS 
Cell culture: HEK 293T cells were grown at 37°C in DMEM supplemented 
with 10% FBS.  
Mutagenesis of plasmids: pEGFP-Mel-18 plasmid mutations, including the 
Δ17–56 mutant of Mel-18 (ring finger deletion referred to as RINGΔ) and the 
C53G and C56G substitution mutants, were generated using the QuickChange 
mutagenesis method (Stratagene, La Jolla, CA) according to the manufacturer’s 
protocol. PCR amplifications were performed using the following program: 95°C 
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for 30 s, 25× (95°C for 30 s, 55°C for 1 min, 68°C for 12 min). Mutations were 
confirmed by DNA sequencing.  
Immunoprecipitation analysis: For co-immunoprecipitation experiments, 
HEK 293 cells were transfected with GFP-Mel-18 expression constructs (wild-
type, ring finger deletion (RINGΔ), C53G, or C56G mutations) using jetPEI 
reagent according to the manufacturer’s instructions (polyplus-transfection, New 
York, NY), and then blocked in mitosis by treatment with 400 ng/ml nocodazole 
for 16 h. After 48 h transfected cells were extracted on ice with NP-40 lysis buffer 
(1% NP-40, 50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM dithiothreitol, and 
complete protease inhibitor cocktail (Roche Applied Science)) for 20 min. Lysates 
were then cleared by centrifugation at 16,438 g for 10 min at 4 °C. Supernatants 
were precleared by incubation with goat (control) IgG and protein G-sepharose 
beads for 2 h at 4 °C with gentle rotation. Precleared extracts were then 
incubated with primary goat polyclonal RanGAP1 antibody or control IgG and 
50% slurry of protein G-sepharose for 4 h at 4 °C with rotation. After washing 
beads six times for 5 min each at 4 °C with NP-40 buffer, bound proteins were 
released by boiling in SDS–PAGE sample dye and analyzed by Western blot 
using the GFP mouse monoclonal antibody (JL-8 clone, Invitrogen). For 
immunoprecipitation analysis of RanGAP1 sumoylation, HEK 293T cells were 
transfected with pEGFP-Mel-18 (wild-type or mutants) or pEGFP-C1 along with 
the myc-sumo-1 expression plasmid using jetPEI reagent according to the 
manufacturer’s instructions (polyplus-transfection). After 48 hours cell extracts 
were prepared using NP-40 Buffer (50 mM Tris–HCl, (pH 8.0), 150 mM NaCl, 1% 
Nonidet P-40, 1 mM dithiothreitol, and complete protease inhibitor cocktail 
(Roche Applied Science), 10 mM N-ethylmaleimide) before adding RanGAP1 
polyclonal antibodies or non-specific IgG to proceed as described above, 
followed by Western blot assay using anti-myc monoclonal antibody (Invitrogen) 
or anti-SUMO-1 antibodies (Bethyl). This assay was normalized with cell number. 
In vitro sumoylation assay: T7-RanGAP1 Δ419 (gift of Mike Matunis) was 
in vitro translated in a rabbit reticulocyte lysates using the TNT-coupled 
transcription-translation system (Promega) with 35S methionine at 30º C for 2 h. 
Then in vitro translated product was incubated with Ubc9 and GST-SUMO-1 in 
reaction buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl2, 2mM ATP, 
1 mM dithiothreitol) at 30°C for 1 h (44) in the presence or absence of purified 
recombinant GST-Mel-18 or GST. Samples were resolved out on SDS-PAGE 
gels. 
 
RESULTS 
Our previous study showed that Mel-18 interacts with HSF2 and inhibits its 
sumoylation by binding to and inhibiting the activity of Ubc9 enzymes in the 
vicinity of HSF2 (108). The results also suggested that Mel-18 inhibits the 
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sumoylation of other cellular proteins. RanGAP1 is a very important cellular 
SUMO substrate protein, in fact the first identified substrate for SUMO-1 
conjugation (37,38). Therefore, in the present study we sought to determine 
whether the sumoylation of RanGAP1 is regulated by Mel-18, and if so whether 
this involves interaction between these two proteins. 
As a first test of this hypothesis, we determined whether adding purified 
recombinant GST-Mel-18 would affect the SUMO modification of RanGAP1 in an 
in vitro sumoylation assay. The results of this experiment, shown in Figure 3.1A, 
indicate that the addition of purified GST-Mel-18 is indeed associated with 
decreased sumoylation of RanGAP1. Next, we wanted to examine whether Mel-
18 can inhibit the sumoylation of RanGAP1 expressed in cells. To test this, GFP-
Mel-18 or GFP expression constructs, along with a myc-SUMO-1 expression 
plasmid, were transfected into cells and then extracts of these cells were 
subjected to immunoprecipitation using anti-RanGAP1 antibodies or non-specific 
IgG (negative control), followed by anti-myc Western blot to detect the 
sumoylated forms of the RanGAP1 protein. The immunoprecipitates were also 
subjected to Western blot using anti-RanGAP1 antibodies in order to provide an 
additional way to visualize the sumoylated form of RanGAP1. The results of this 
experiment, shown in Figure 3.1B, indicate that expression of GFP-Mel-18, but 
not GFP, is associated with decreased RanGAP1 sumoylation. The results of the 
experiments shown in Figure 3.1 demonstrate the ability of Mel-18 to inhibit 
RanGAP1 sumoylation. 
As described above, our previous work demonstrated that Mel-18 binds to 
HSF2 and inhibit its sumoylation (108). Therefore, we next investigated whether 
the inhibition of RanGAP1 sumoylation demonstrated by the data in Figure 3.1 
above could also involve interaction between RanGAP1 and Mel-18. To examine 
this, HEK 293 cells were transfected with GFP-Mel-18 expression constructs and 
then extracts of the cells were subjected to immunoprecipitation with anti-
RanGAP1 antibodies or non-specific IgG (negative control), followed by anti-GFP 
antibody Western blot (Figure 3.2A). As a complementary approach, we 
preformed the reverse approach of subjecting extracts of these transfected cells 
to immunoprecipitation with anti-GFP antibodies or non-specific IgG (negative 
control), followed by Western blot using anti-RanGAP1 antibodies (Figure 3.2B). 
The results of these experiments both indicate that RanGAP1 and Mel-18 
proteins expressed in cells do interact. 
Although it has been described that RanGAP1 remains SUMO modified 
during mitosis (110), it is still unclear whether the SUMO level is changed during 
this part of the cell cycle. Our previous finding showed that increased 
sumoylation of HSF2 in mitosis is coupled with decreased interaction between 
HSF2 and Mel-18, so we hypothesized that RanGAP1 may also exhibit mitotic-
dependent regulation of its sumoylation, which might be associated with different 
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interaction level with Mel-18 during this stage of the cell cycle. As a first test of 
this hypothesis, extracts of asynchronous or mitotic HEK 293 cells were 
immunoprecipitated using anti-RanGAP1 antibodies or non-specific IgG and the 
immunoprecipitates were subjected to Western blot using anti-SUMO-1 
antibodies (top panel) or anti-RanGAP1 antibodies (middle panel) (Figure 3.3A). 
The results of this experiment indicate that sumoylation of RanGAP1 is 
decreased during mitosis. 
Next, we wanted to determine whether this mitotic-dependent decrease in 
RanGAP1 sumoylation is associated with increased interaction between Mel-18 
and RanGAP1 during this part of the cell cycle, as predicted by our hypothesis. 
To test this, HEK 293 cells were transfected with GFP-Mel-18 expression 
constructs, and then extracts of asynchronous or mitotic transfected HEK 293 
cells were immunoprecipitated using anti-RanGAP1 antibodies and the 
immunoprecipitates subjected to Western blot using anti-GFP antibodies. The 
results of this experiment indicate that higher levels of interaction between 
RanGAP1 and Mel-18 are indeed observed in extracts of mitotic cells compared 
to those of asynchronous cells (Fig 3.3B). 
The Mel-18 protein contains a RING finger domain in its N-terminal region 
(111-113). To test whether this RING domain is important for the ability of Mel-18 
to interact with RanGAP1 or inhibit RanGAP1 sumoylation, we made mutant 
GFP-Mel-18 plasmids with a RING finger deletion (RINGΔ) or cysteine-to-glycine 
substitutions at key cysteine residues 53 and 56 of the RING domain (C53G, 
C56G). First, to test the importance of the RING finger for Mel-18 interaction with 
RanGAP1, HEK 293 cells were transfected with the wild-type or mutant (RINGΔ, 
C53G, or C56G) GFP-Mel-18 constructs along with the myc-SUMO-1 expression 
plasmid, and then extracts of the transfected cells were subjected to 
immunoprecipitation using anti-RanGAP1 antibodies or non-specific IgG followed 
by Western blot of the immunoprecipitates with anti-GFP antibodies (Figure 3.4A). 
The results indicate that none of the RING finger mutations appear to affect Mel-
18 interaction with RanGAP1. To examine their effect on RanGAP1 sumoylation, 
HEK 293 cells transfected with these constructs along with the myc-SUMO-1 
expression plasmid were subjected to immunoprecipitation using anti-RanGAP1 
antibodies or non-specific IgG, followed by Western blot of the 
immunoprecipitates with anti-myc antibodies to detect sumoylated RanGAP1. 
The results, shown in Figure 3.4B, indicate that deletion of the RING domain or 
mutation of cysteines 53 or 56 also has no effect on RanGAP1 sumoylation. 
 
CONCLUSION 
The results presented in this chapter show that Mel-18 not only acts as an 
anti-SUMO E3 factor for the HSF2 protein, but for RanGAP1 as well. This finding 
increases the likelihood that Mel-18 regulates the sumoylation of other, as-yet-
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undiscovered cellular proteins. Indeed, our previous results indicated that there 
are many sumoylated bands on SDS–PAGE gels whose amounts change 
significantly in response to changes in Mel-18 level, indicating that Mel-18 may in 
fact regulate the sumoylation of a large number of proteins. Thus, one important 
goal of future studies is to identify these other targets whose SUMO modification 
is modulated by Mel-18. Mel-18 is known to act as a tumor suppressor, and so it 
would be particularly exciting if it was found to regulate the sumoylation of 
cellular proteins involved in the control of cell proliferation. 
Another intriguing finding of this paper is that the cell cycle-dependence of 
the interaction between Mel-18 and HSF2 vs. RanGAP1 are exactly the opposite 
of each other: HSF2 interaction with Mel-18 decreases during mitosis, resulting in 
elevated HSF2 sumoylation, in contrast to higher interaction of RanGAP1 and 
Mel-18 and less RanGAP1 sumoylation during this stage of the cell cycle. This 
suggests that there is a mechanism or mechanisms for differentially controlling 
Mel-18 interaction with partners in a mitosis-dependent manner. Future studies 
into this area would likely reveal valuable insight into the regulation of the anti-
SUMO E3 function of Mel-18. 
Finally, our results indicate that the conserved RING finger motif of Mel-18, 
found in its N-terminal region (111-113), is not required for its interaction with 
RanGAP1 or its ability to inhibit RanGAP1 sumoylation. Since the results of our 
previous study suggested that Mel-18 interaction with the SUMO E2 enzyme 
Ubc9 is likely important for the sumoylation-inhibitory function of Mel-18 (108), 
this suggests that other regions of the Mel-18 protein are involved in binding 
RanGAP1 and Ubc9. Future studies to identify these regions would reveal 
important new functional domains of the Mel-18 protein. 
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Figure 3.1 Mel-18 inhibits RanGAP1 sumoylation 
(A) Purified Mel-18 inhibits in vitro sumoylation of RanGAP1. 35S-labeled in vitro 
translated T7-RanGAP1 419 RanGAP1 fragment was subjected to in vitro 
sumoylation in the absence of any additional purified proteins (lane 2), or in the 
presence of purified GST (lane 3) or GST-Mel-18 (lane 4). Samples were then 
analyzed by SDS–PAGE and autoradiography (top panel). The anti-GST 
Western blot (lower panel) shows the relative amounts of GST-Mel-18 or GST 
that were added to the reactions in lanes 3 and 4 of the top panel, respectively. 
(B) Mel-18 inhibits sumoylation of RanGAP1 in vivo. HEK 293 cells were 
transfected with GFP-Mel-18 or GFP expression constructs along with myc-
SUMO-1 expression plasmid, and then extracts of the cells were subjected to 
immunoprecipitation with anti-RanGAP1 antibodies or non-specific IgG (negative 
control), followed by anti-myc Western blot to detect the sumoylated forms of 
RanGAP1, and to Western blot using anti-RanGAP1 antibodies. The cell lysates 
were subjected to anti-GFP Western blot to analyze expression levels of GFP-
Mel-18 and GFP, and to anti-b-actin Western as a loading control. This figure is 
representative of this experiment performed minimally 3 times. 
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Figure 3.2 RanGAP1 interacts with Mel-18. 
(A) HEK 293 cells were transfected with GFP-Mel-18 expression constructs, and 
then extracts of the cells were subjected to immunoprecipitation with anti-
RanGAP1 antibodies or non-specific IgG (negative control), followed by anti-GFP 
Western blot to detect the interaction between Mel-18 and RanGAP1. (B) A 
similar experiment to that described in (A) was performed, except that here the 
cell extracts were subjected to immunoprecipitation with anti-GFP antibodies or 
non-specific IgG (negative control), followed by anti-RanGAP1 Western blot. This 
figure is representative of this experiment performed minimally 3 times. 
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Figure 3.3 Decreased RanGAP1 sumoylation and increased interaction 
between RanGAP1 and Mel-18 during mitosis.  
(A) Sumoylation of RanGAP1 decreases during mitosis. Extracts of 
asynchronous or mitotic HEK 293 cells were immunoprecipitated using anti-
RanGAP1 (goat polyclonal) antibodies and the immunoprecipitates subjected to 
Western blot using anti-SUMO-1 antibodies (top panel) or anti-RanGAP1 
antibodies (middle panel). The cell lysates were subjected to anti-b-actin Western 
blot as a loading control (bottom panel). (B) Interaction between RanGAP1 and 
Mel-18 increases during mitosis. HEK 293 cells were transfected with GFP-Mel-
18 expression constructs, and then extracts of asynchronous or mitotic 
transfected cells were immunoprecipitated using anti-RanGAP1 antibodies or 
non-specific IgG and the immunoprecipitates subjected to Western blot using 
anti-GFP antibodies (top panel). The cell lysates were subjected to anti--actin 
Western blot as a loading control (bottom panel). This figure is representative of 
this experiment performed 2 times. 
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Figure 3.4 RING finger domain of Mel-18 is not required for its interaction 
with RanGAP1 or inhibition of RanGAP1 sumoylation.  
(A) HEK 293 cells were transfected with GFP-Mel-18 expression constructs (wild-
type, ring finger deletion, C53G, or C56G mutations), along with the myc-SUMO-
1 expression plasmid. Extracts of the transfected cells were immunoprecipitated 
using anti-RanGAP1 antibodies or nonspecific IgG and the immunoprecipitates 
subjected to Western blot using anti-GFP antibodies (top panel). (B) As in (A), 
except that here the anti-RanGAP1 or nonspecific IgG immunoprecipitates were 
subjected to Western blot using anti-myc antibodies to examine the levels of 
sumoylated RanGAP1. The anti-RanGAP1 immunoprecipitates were also 
subjected to anti-RanGAP1 Western blot to normalize for levels of RanGAP1. 
This figure is representative of this experiment performed minimally 3 times. 
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CHAPTER FOUR: 
IDENTIFICATION OF A RING FINGER POLYMORPHISM OF HUMAN BMI-1 
THAT CAUSES ITS DEGRADATION BY THE UBIQUITIN-PROTEASOME 
SYSTEM  
 
BACKGROUND 
Bmi-1 is a member of the polycomb group family of proteins, which function 
as negative regulators of the transcription of a number of important target genes 
(114). Bmi-1 was first cloned as a c-myc cooperating oncogene in murine 
lymphomas (65,66), and found to have significant sequence relatedness to 
Drosophila polycomb proteins(66).  Previous studies have identified several ways 
in which Bmi-1 mediates its effects on cell proliferation, including inhibiting 
expression of the Ink4A/ARF locus(68,85), modulating the p21-Rb pathway (69), 
and inducing telomerase activity (70).   
In addition to its function as an oncogene, Bmi-1 also plays important roles 
in determination of cell fate and stem cell renewal of the neural, hematopoietic, 
and other cell lineages (67,71-77).  Bmi-1 contains a conserved RING finger 
domain near the NH2 terminus, which is important for the function of this protein 
(65,70,78-80,82).  Bmi-1 has been found to be predominantly localized to the 
nucleus, which is mediated by a nuclear localization sequence (NLS) located in 
the C-terminal region of this protein (70,78,115). 
 In this paper we characterize a polymorphism in the human Bmi-1 protein 
that changes a cysteine in the RING finger domain (cysteine 18) to tyrosine.  The 
results show that the C18Y polymorphism results in a significant reduction in 
levels of the Bmi-1 protein by leading to its ubiquitination and destruction by the 
proteasome.  In light of the important functions of Bmi-1 in stem cell renewal and 
determination of cellular identity, these results suggest that this C18Y 
polymorphism could have deleterious effects in the people that have it. 
 
MATERIALS AND METHODS 
SNP database searching: To identify potential polymorphisms within the 
Bmi-1 gene, we searched the dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP/index.html). This search identified a SNP 
polymorphism (rs1042059) that is predicted to change the cysteine at amino acid 
18 of Bmi-1 to tyrosine.  This Bmi-1 C18Y polymorphism was found in both the 
CEU (Utah residents with ancestry from northern and western Europe) and YRI 
(Yoruba in Ibadan, Nigeria) populations that are part of the International HapMap 
Project. 
Cell culture and plasmids: HeLa-ATCC cells and HEK 293T cells were 
grown at 37°C in DMEM supplemented with 10% FBS and 100x antibiotic-
antimycotic (Invitrogen) in 5% CO2.  pEGFP-Bmi-1 plasmid was generated by 
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using PCR to amplify from the plasmid pOTB7-hBmi-1 cDNA (Accession number 
BC011652, Open Biosystems, Huntsville, AL) a coding fragment of Bmi-1 having 
KpnI and BamHI sites at the ends using the following primers: 5′-GCG GGT 
ACC ATG CAT CGA ACA ACG AGA-3′ and 5′- CGC GGA TCC TCA ACC 
AGA AGA AGT TGC TGA-3′. PCR amplifications were performed using the 
following program: 95°C for 5 min, 30× (95°C for 1 min, 59°C for 1 min, 72°C for 
2 min), 72°C for 5 min This PCR product was then cloned into pEGFP-C1 vector 
(Clontech, Mountain View, CA) at the KpnI and BamHI sites to make the pEGFP-
Bmi-1 plasmid.  This plasmid was confirmed by DNA sequencing.  pEGFP-C18Y-
Bmi-1 plasmid was generated using the QuickChange mutagenesis method 
(Stratagene) according to the manufacturer’s protocol.  PCR amplifications were 
performed using the following program: 95°C for 30 s, 18× (95°C for 30 s, 55°C 
for 1 min, 68°C for 12 min). The mutation was confirmed by DNA sequencing.  
Fluorescence microscopy: HEK293T cells were seeded onto coverslips 
that were acid-washed and flamed, and then coated with laminin (5 µg/ml) 
(Sigma-Aldrich, St. Louis, MO). 48 h after transfection with the wild-type or C18Y 
GFP-Bmi-1 fusion proteins, cells were washed twice in ice-cold 1× PBS, followed 
by fixation in 3.7% paraformaldehyde for 20 minutes at room temperature.  After 
a final wash with PBS, coverslips were mounted on a slide with Vectashield 
mounting medium plus 1.5 µg/ml DAPI (4', 6 diamidino-2-phenylindole) (Vector 
Laboratories, Burlingame, CA).  Fluorescence of the GFP-Bmi-1 proteins was 
visualized using a Nikon fluorescent microscope with a 100x oil immersion 
objective and a Nikon Spotcam digital-imaging camera. 
Extract preparation and Western blot assay: HEK293 cells were 
transfected with the wild-type or C18Y GFP-Bmi-1 expression plasmids using 
Jet-PEI reagent according to the manufacturer’s instructions. At 48 h post-
transfection, cells were extracted on ice with NP-40 lysis buffer (1% NP-40, 50 
mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM dithiothreitol, complete protease 
inhibitor cocktail (Roche Applied Science) and 20 mM N-ethylmaleimide (added 
fresh)) for 20 minutes.  After centrifugation at 16,438 g at 4°C for 10 minutes, the 
supernatant was transferred to a fresh tube, and then the whole cell lysate was 
used for the following assays: SDS-PAGE and Western blot were performed 
according to standard protocols.  The antibodies and dilutions used to probe the 
Western blots were as follows.  Goat anti-GFP antibody (Bethyl Laboratories, Inc.) 
was used at 1:2,000.  For the immunoprecipitation assay of ubiquitinated Bmi-1, 
mouse monoclonal anti-ubiquitin antibody (gift of Dr. Haining Zhu, University of 
Kentucky, Lexington, KY) was used at 1:1,000. This assay was normalized with 
cell number. 
Proteasome Inhibition Assay: HEK293T cells were transfected with the 
wild-type or C18Y GFP-Bmi-1 expression plasmids as described above, except 
that at 44 h post-transfection 10 µM MG132 proteasome inhibitor (Calbiochem, 
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Gibbstown, NJ, gift of Dr. Dan Noonan, University of Kentucky, Lexington, KY) 
was added and incubated for 4 hours. This assay was normalized with cell 
number. 
Bmi-1 Ubiquitination Assay: HEK293T cells were transfected with 
pEGFP-Bmi-1 or pEGFP-C18Y-Bmi-1 as described above.  At 48 hours post-
transfection, cells were extracted on ice with NP-40 lysis buffer (1% NP-40, 50 
mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM dithiothreitol, complete protease 
inhibitor cocktail (Roche Applied Science) and 20 mM N-ethylmaleimide (added 
fresh)) for 20 minutes.  Lysates were then cleared by centrifugation at 16,438 g 
for 10 minutes at 4°C. Supernatants were precleared by incubation with goat 
(control) IgG and protein G-sepharose beads for 2 hours at 4°C with gentle 
rotation.  Precleared extracts were then incubated with primary goat polyclonal 
anti-GFP antibody or control IgG and 50% slurry of protein G-sepharose for 4 
hours at 4°C with rotation.  After washing beads 6 times for 5 minutes each at 
4°C with NP-40 buffer, bound proteins were released by boiling in SDS-PAGE 
sample dye and analyzed by Western blot assay using the anti-ubiquitin mouse 
monoclonal antibody or anti-GFP goat polyclonal antibody. This assay was 
normalized with cell number. 
 
RESULTS 
As depicted in Figure 4.1A, the Bmi-1 protein contains a RING finger 
domain in its N-terminal region (65,70,78-80,82).  Examination of the dbSNP 
database revealed the existence of a polymorphism in human Bmi-1 that 
changes amino acid 18, a cysteine in the RING finger domain, to tyrosine (Figure 
4.1B).  Further analysis revealed that this polymorphism is found heterozygous in 
individuals of both the CEU (Utah residents with ancestry from northern and 
western Europe) and YRI (Yoruba in Ibadan, Nigeria) populations that are part of 
the International HapMap Project. 
Because the cysteine that is changed to tyrosine in this polymorphism is a 
residue of the RING finger domain, we hypothesized that this alteration could 
lead to alteration in the functional properties of the Bmi-1 protein.  Bmi-1 has 
been found to be a predominantly nuclear-localized protein (70,78,115), 
mediated by a nuclear localization sequence (NLS) in the C-terminal region 
(Figure 4.1A) (70,78). Therefore, one functional property of Bmi-1 we 
hypothesized could be affected by the C18Y polymorphism is its pattern of 
localization within the cell.  To test this hypothesis we transfected wild-type and 
C18Y GFP-Bmi-1 expression plasmids into HEK293 cells and then examined the 
sub-cellular localization of the transfected proteins using fluorescence 
microscopy analysis.  The results of this experiment, shown in Figure 4.2, 
revealed that the wild-type and C18Y Bmi-1 proteins both exhibit predominant 
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nuclear localization, indicating that the C18Y polymorphism does not appear to 
significantly alter the subcellular localization of the Bmi-1 protein.   
Although the results of the fluorescence microscopy experiment shown in 
Figure 4.2 did not indicate a difference in localization, they did show that the 
intensity of the signal from the C18Y GFP-Bmi-1 was markedly less than that 
exhibited by wild-type Bmi-1.  This suggested that the C18Y polymorphism may 
be associated with a decrease in levels of the Bmi-1 protein.  To test this we 
subjected extracts of HEK293 cells transfected with the wild-type or C18Y GFP-
Bmi-1 expression plasmids to Western blot assay with anti-GFP antibodies to 
detect the transfected Bmi-1 proteins, or with β-actin antibodies as a loading 
control.  The results of this experiment show that the levels of the C18Y GFP-
Bmi-1 protein are indeed significantly lower than that of the wild-type GFP-Bmi-1 
(Figure 4.3). 
We hypothesized that the C18Y polymorphism could be resulting in 
decreased levels of Bmi-1 by leading to increased destruction of this protein by 
the ubiquitin-proteasome degradation pathway. To test this hypothesis, we 
subjected extracts of HEK293 cells transfected with the wild-type or C18Y GFP-
Bmi-1 expression plasmids to immunoprecipitation using anti-GFP antibodies or 
non-specific IgG control antibodies, followed Western blot assay with anti-
ubiquitin antibodies to compare the amounts of ubiquitinated forms of the 
transfected wild-type vs. C18Y Bmi-1 proteins.  The results of this analysis, 
shown in Figure 4.4A, indicate that C18Y Bmi-1 exhibits significantly higher 
levels of ubiquitination than wild-type Bmi-1.  Next, to test the involvement of the 
proteasome in the lower protein levels of C18Y Bmi-1, we tested whether levels 
of this form of Bmi-1 increase in cells that have been treated with the proteasome 
inhibitor MG-132.  The results of this experiment show that MG-132 treatment 
does indeed result in the presence of significantly higher levels of the C18Y Bmi-
1 protein (Figure 4.4B).  The results shown in Figure 4 support the hypothesis 
that the C18Y polymorphism of Bmi-1 leads to lower levels of this protein by 
causing its turnover by the ubiquitin-proteasome degradation pathway. 
 
CONCLUSION 
The results described in this part characterize a polymorphism in the human 
Bmi-1 protein that changes the cysteine at amino acid position 18 to tyrosine 
(C18Y). The results also show that the C18Y substitution causes a significant 
reduction in Bmi-1 protein levels and that this is associated with increased 
ubiquitination leading to degradation by the proteasome. This is the first 
demonstration of a polymorphism in human Bmi-1 that leads to alteration in 
levels of this important protein. 
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Figure 4.1  Identification of a SNP resulting in a C18Y polymorphism of 
Bmi-1. 
(A) Schematic showing the location of the RING finger and NLS in the Bmi-1 
protein, as well as its nuclear localization sequence (NLS). (B) Schematic 
showing the amino acid sequence of the RING finger domain and location of the 
C18Y polymorphism of Bmi-1.   
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Figure 4.2 Fluorescence microscopy analysis of wild-type and C18Y Bmi-1 
localization in cells. 
(A) Wild-type and C18Y GFP-Bmi-1 expression plasmids were transfected into 
HEK 293T cells, and the subcellular localization of the GFP–Bmi-1 proteins 
examined by fluorescence microscopy. GFP images shown are 1.25 second 
exposures. DNA was visualized by staining with DAPI. (B) Fluorescence 
microscopy analysis of wild-type GFP-Bmi-1 taken at shorter exposure time for 
the GFP channel (0.45 second) than that shown in panel A. This figure is 
representative of this experiment performed minimally 3 times. 
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Figure 4.3 C18Y polymorphism is associated with a significant decrease in 
Bmi-1 protein level. 
Wild-type or C18Y GFP-Bmi-1 expression plasmids were transfected into 
HEK293 cells, and then extracts prepared from the transfected cells were 
subjected to Western blot assay using anti-GFP antibodies (upper panel), or anti-
-actin antibodies as a loading control (lower panel). This figure is representative 
of this experiment performed minimally 3 times. 
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Figure 4.4 C18Y Bmi-1 protein is degraded by the ubiquitin-proteasome 
system. 
(A) HEK293 cells were transfected with wild-type or C18Y GFP-Bmi-1 expression 
plasmids, and then extracts of the cells were subjected to immunoprecipitation 
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with anti-GFP antibodies (goat polyclonal) or non-specific IgG (negative control), 
followed by anti-ubiquitin Western blot to detect the ubiquitinated forms of Bmi-1, 
and to Western blot using goat polyclonal anti-GFP antibodies. (B) Wild-type or 
C18Y GFP-Bmi-1 expression plasmids were transfected into HEK293 cells, in the 
absence or presence of 10 µM MG132 proteasome inhibitor (inhibitor added at 
44 h post-transfection and incubated for 4 hours). Extracts prepared from the 
transfected cells were then subjected to Western blot assay using anti-GFP 
antibodies (upper panel), or anti--actin antibodies as a loading control (lower 
panel). This figure is representative of this experiment performed minimally 3 
times. 
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CHAPTER FIVE:  
DISCUSSION and Future Directions 
 
I. Mel-18 is a novel anti-SUMO E3 protein. 
Previous studies showed little evidence of anti-SUMO E3 proteins. Our 
research is the first that suggests that Mel-18 actually functions as an anti-SUMO 
E3 protein, because like a traditional SUMO E3 protein it interacts both with the 
SUMO E2 enzyme Ubc9 and sumoylation substrate proteins (HSF2/RanGAP1), 
but instead of stimulating SUMO modifications of HSF2/RanGAP1, it inhibits 
them by binding to and inhibiting the activity of SUMO E2 (Ubc9) enzymes in the 
vicinity of the HSF2/RanGAP1 proteins. This is in contrast to the sumoylation-
stimulating activities of another polycomb protein, Pc2, a traditional SUMO E3, 
indicating that members of the polycomb group of proteins are involved in both 
the positive and negative regulation of protein sumoylation through their 
interactions with Ubc9 and substrate proteins. Future studies investigating 
whether additional polycomb proteins act as positive or negative regulators of the 
sumoylation of proteins in cells would likely provide important insights into both 
the regulation of protein sumoylation and the mechanisms by which polycomb 
proteins mediate their important biological functions. 
Mel-18 has a well conserved RING finger motif at its N-terminal region, 
which is shown to be important in DNA binding and homodimerization (63); 
however our results indicate that this domain is not required for its interaction 
with RanGAP1 or its ability to inhibit RanGAP1 sumoylation. Since these results 
also demonstrated that Mel-18 interaction with the SUMO E2 enzyme Ubc9 is 
likely important for the sumoylation-inhibitory function of Mel-18, this suggests 
that other regions of the Mel-18 protein are involved in binding RanGAP1 and 
Ubc9. Future studies to identify these regions would reveal important new 
functional domains of the Mel-18 protein. This would also support our hypothesis 
that Mel-18, like Pc2, has multiple domains contributing to its anti-SUMO E3 
activities. A carboxyl-terminal fragment of Pc2 can form a scaffold by recruiting 
E2 (Ubc9) and substrate (CtBP), and this region can also interact with the amino-
terminal domain, which will facilitate the transfer of SUMO from E2 to substrate. 
Besides the conserved RING domain at the N-terminal region (Cys18 ~ Cys56), 
Mel-18 also has other two important domains: well conserved HTH structure in 
the middle region (Lys158 ~ Val229), that is important in homodimerization (63), 
and a Proline/serine-rich domain (P/S domain) in the C-terminal region (Gln230 ~ 
Thr344), that is important in protein- protein interactions, such as binding with 
cyclin D2 (61). Our study of yeast two-hybrid screening showed that the 
interaction region of Mel-18 with HSF2 localizes to amino acids 144-270, so we 
can perform in vitro binding or yeast two hybrid assays to identify the interaction 
region of Mel-18 with RanGAP-1, as well as Ubc-9. We can also do the Ubc9 
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preloading assay to test which domain(s) will contribute to the anti-SUMO E3 
activities of Mel-18 (34). 
We propose two possible models for Mel-18 acting as an anti-SUMO E3 
protein: I. Keeping Ubc9 away from substrates, such as HSF2/RanGAP1. This 
hypothesis is based on the adaptor model of most SUMO E3 proteins, such as 
Pc2. The carboxyl-terminal region of Pc2 functions as a scaffold, recruits E2 
(Ubc9) and substrate (CtBP), and facilitates its sumoylation II. Allosterical 
conformation change of Ubc-9 and/or substrates by Mel-18: This hypothesis of 
decreased affinity between Ubc-9 and substrates by conformation change is 
based on the RanBP2 study reports: RanBP2, SUMO-1 E3 ligase, can 
allosterically change Ubc-9 conformation and induce increased affinity for 
specific substrates (33).  
Mel-18 can work in one of these two models or both of them. To test 
whether Mel-18 keeps Ubc-9 from substrates, we can utilize the cross-linking 
technique. Cells will be transfected with GFP-Mel-18 or GFP constructs, and then 
cell extracts will be subjected to immunoprecipitation assay after cross- linking 
treatments. By comparison of the complexes levels of Ubc-9 and substrates, we 
can know whether Ubc-9 is kept away from substrates by Mel-18. Allosterical 
conformation change of Ubc-9 and substrates by Mel-18 can be detected by the 
change of infrared (IR), UV, or CD spectra when associated with Mel-18 binding 
(116). 
Another intriguing finding is that the cell cycle dependence of the interaction 
between Mel-18 and HSF2 vs. Ran-GAP1 are exactly the opposite of each other: 
HSF2 interaction with Mel-18 decreases during mitosis, resulting in elevated 
HSF2 sumoylation, in contrast to higher interaction of RanGAP1 and Mel-18 and 
less RanGAP1 sumoylation during this stage of the cell cycle. This suggests that 
there is a mechanism or mechanisms for differentially controlling Mel-18 
interaction with partners in a mitosis-dependent manner. We propose a potential 
mechanism for regulating the anti-SUMO E3 activities of Mel-18 by different 
phosphorylation levels during different cell cycle phases. Previous studies 
showed that the dephosphorylated form of Mel-18 dissociates from chromatin 
during mitosis (64). Meanwhile, it was also reported that many PcG proteins will 
dissociate from the chromatin during mitosis, and disperse into the cytoplasm 
(117). Consistent with those findings, our studies also indicate that Mel-18 will 
mainly localize to the cytoplasm during mitotic phase (results not shown). 
Therefore, we hypothesize that different interaction levels between Mel-18 and 
HSF2/RanGAP1 in the interphase and mitosis are regulated by the 
phosphorylation states of Mel-18. During interphase, Mel-18 is phosphorylated 
and colocalizes with HSF2 in the nucleus, but not with RanGAP1 which localizes 
in the cytoplasm. In the mitosis, Mel-18 is dephosphorylated and dispersed from 
nucleus to cytoplasm, where RanGAP1 localizes, but HSF2 still localizes in 
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nucleus, so Mel-18 interaction with HSF2 decreases, but increases for RanGAP1 
during mitosis (Figure 5.1). 
My results show that Mel-18 not only acts as an anti-SUMO E3 factor for the 
HSF2 protein, but for Ran- GAP1 as well. These results also indicate that Mel-18 
is able to inhibit conjugation of SUMO-1 to proteins, suggesting that Mel-18 likely 
inhibits the sumoylation of other proteins in addition to HSF2/RanGAP1, perhaps 
even acting to down-regulate sumoylation in cells globally. This finding increases 
the likelihood that Mel-18 regulates the sumoylation of other, as-yet-
undiscovered cellular proteins. Thus, one important goal of future studies would 
be to identify these other targets whose SUMO modification is modulated by Mel-
18. Meanwhile, Mel-18 is shown to have tumor suppressor activities, which are 
associated with c-myc/cdc25 pathway or regulation of cyclin D2, so we propose 
its anti-SUMO E3 activities could contribute to another novel mechanism for Mel-
18 as a tumor suppressor. In support of this hypothesis, studies showed that 
many oncogenic proteins or tumor suppressor, such as P-53, PML, MDM2 and c-
jun  (118-121), are sumo modified, and their sumoylation levels change in tumor 
cells. It would be particularly exciting if Mel-18 is found to regulate the 
sumoylation of cellular proteins involved in the control of cell proliferation. To test 
this hypothesis, we could compare the protein sumoylation levels in cells 
overexpressing Mel-18 with those in control cells and then use Mass 
Spectrometry to identify candidate proteins with different sumoylation levels in 
both groups. This study would also provide insights that could make Mel-18 as a 
potential target site for pharmaceutics cancer treatments. 
In summary, the results of our study, show that Mel-18 functions as an anti-
SUMO E3 protein, interacting both with HSF2/RanGAP1 and the SUMO E2 Ubc9, 
but acting to inhibit Ubc9 activity in order to decrease sumoylation of target 
proteins, such as HSF2 and RanGAP1, and that these activities do not require 
the RING domain of Mel-18. The results also show that RanGAP1 sumoylation is 
decreased during mitosis, and that this is associated with increased interaction 
between RanGAP1 and Mel-18 during this stage of the cell cycle. Intriguingly, 
this regulatory relationship is the opposite of that found for Mel-18 and HSF2, in 
which the interaction between these two proteins decreases during mitosis, 
resulting in elevated HSF2 sumoylation. 
 
II. C18Y polymorphism of Bmi-1 is associated with increased 
ubiquitination leading to increased degradation by the proteasome. 
The results described in chapter 4 characterize a polymorphism in the 
human Bmi-1 protein that changes the cysteine at amino acid position 18 to a 
tyrosine (C18Y).  The results also show that the C18Y substitution causes a 
significant reduction in steady state Bmi-1 protein levels and that this is 
associated with increased ubiquitination, presumably leading to degradation by 
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the proteasome. This is the first demonstration of a polymorphism in human Bmi-
1 that leads to alteration in levels of this important protein. Cysteine 18 is part of 
the RING finger motif responsible for binding zinc. Thus, we hypothesize that the 
most likely explanation for the decreased level of C18Y Bmi-1 is that changing 
this cysteine to tyrosine disrupts the structure of the RING domain, leading to its 
recognition as a mal-folded protein by the ubiquitination machinery, covalent 
ubiquitin attachment, and subsequent degradation by the proteasome. 
Bmi-1 is important for the determination of cell fate and the renewal of adult 
stem cells of a number of cell lineages, including neural, hematopoietic, and 
intestinal lineages (67,71-77,122).  Since the C18Y Bmi-1 polymorphism causes 
a significant decrease in Bmi-1 levels, we hypothesize that people with the C18Y 
form of Bmi-1 may be affected by problems such as decreased ability to renew 
stem cells. The individuals identified in the SNP database as having this 
polymorphism, who belong to the CEU (Utah residents with ancestry from 
northern and western Europe) and YRI (Yoruba in Ibadan, Nigeria) populations of 
the International HapMap Project, are heterozygous for it, and thus would be 
expected to have half the normal levels of Bmi-1.  The results of mouse studies 
showing that Bmi-1+/- heterozygote mice, although they are not as severe as 
those observed for Bmi-1-/- mice, do exhibit phenotypic differences in stem cell 
characteristics compared to wild-type mice (74,75,123). Therefore, we 
hypothesize that these people that are heterozygous for C18Y Bmi-1 could 
possibly have been affected in some way in terms of their health. However, 
because the health records of these individuals are not available we can not 
know this, and in any event it is possible that the effects may not be strong 
enough to cause significant symptoms. Our results suggest that individuals that 
are homozygous for C18Y Bmi-1 would have extremely low levels of Bmi-1 
protein. Therefore, based on results showing that Bmi-1-/- mice exhibit significant 
problems resulting in death either days after birth or maximally by approximately 
2 months of age (67,71-77), we would expect that homozygous C18Y individuals 
could experience significant deleterious health effects. 
In addition to its importance for stem cell renewal and cell identity, Bmi-1 
also has oncogenic functions (65,66,68-70,85). Thus, it is conceivable that the 
decreased levels of Bmi-1 expected in people with the C18Y polymorphism could 
be beneficial to these people in terms of decreasing their risk of cancer. In 
support of this, mice lacking Bmi-1 showed a decreased incidence of tumor cells 
(124). Intriguingly, even cells from Bmi-1+/- heterozygous mice showed a 
significant decrease in tumor formation(85), suggesting that individuals with the 
C18Y Bmi-1 polymorphism may have a lower susceptibility to developing tumors. 
In summary, the results of our study, coupled with the results of previous 
studies, suggest that individuals that have the C18Y polymorphism of Bmi-1 
could have health problems related to an inability to renew adult stem cells 
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and/or establishing cell identities.  This is likely to be particularly true in the case 
of an individual is homozygous for this polymorphism, as this person would likely 
have very low levels of Bmi-1, but is not clear if heterozygote C18Y individuals 
would experience significant problems. On the other hand, the decreased levels 
of Bmi-1 protein caused by the C18Y polymorphism may also provide the 
advantage of decreased susceptibility to developing cancer, even in people that 
are only heterozygous for the polymorphism. Future studies are warranted to test 
these hypotheses related to the C18Y Bmi-1 polymorphism. 
 
III. PcG proteins have opposing roles. 
PcG proteins have been shown to work together as complexes to silence 
genes (46-49). Our studies, coupled with other research data, suggest that 
proteins in PcG complexes could also have opposing roles: (a) SUMO E3 and 
anti-SUMO E3 functions: Mel-18 functions like an anti-SUMO E3 protein, 
interacting both with substrates and the SUMO E2 Ubc9 but acting to inhibit 
Ubc9 activity to decrease sumoylation of target proteins (108); Pc2, another Poly-
comb protein stimulates sumoylation of transcriptional corepressor, CtBP 
(34,104); (b) regulation of both SUMO and Ubiquitin pathways: These two 
modifications can have the same target proteins, but cause distinct 
consequences (125), and PcG proteins can regulate both of these two pathways. 
PRC1 complex containing Ring1B protein have H2A-K119 ubiquitin E3 ligase 
activity (52); however, Mel-18 and Pc2 are shown to be anti-SUMO and SUMO E3 
protein, respectively (34,104,108); (c) tumor suppressor(s) and oncogene protein(s): 
Bmi-1 promotes cell proliferation and functions as an oncogene protein (68,85,70). 
Unlike Bmi-1, the highly homologous Mel-18 was shown to have tumor-
suppressive effects and down regulate cell progression (59-62); meanwhile, Hpc-2, 
another PcG protein, can also arrest cells in G2-M phase (126).   
Therefore the amounts of each protein in PcG complexes will determine the 
eventual activities of the whole complex. Quantitative changes of proteins will 
break the internal balance and then affect the quantity or quality of protein 
complexes, and then finally result in the alteration of a set of downstream genes 
and maybe different cell fates. 
49 
 
 
 
Fig 5.1 Different interactions between Mel-18 and HSF2 during different cell 
cycle phases. 
 
In interphase, Mel-18 is phosphorylated and colocalizes with HSF2 in nucleus, 
thereby inhibits HSF2 sumoylation and binding on HSE. In mitosis, Mel-18 is 
dephosphorylated and disperses from nucleus to cytoplasm, but HSF2 remains 
in nucleus, therefore, Mel-18 interaction with HSF2 decreases, HSF2 
sumoylation increases and HSF2 binds on HSE. 
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APPENDIX 
 
Appendix: List of Abbreviations 
 
CDK, Cyclin-dependent kinases 
CtBP, C-terminal Binding Protein 
DAPI, 4’,6-diamidino-2-phenylindole 
DNA, deoxyribonucleic acid 
DTT, dithiothreitol, 
EDTA, ethylene diamine triacetic acid 
FITC, fluorescein isothiocyanate 
FCS, fetal calf serum 
GATA3, GATA binding protein 3 
GFP, green fluorescent protein 
GST, glutathione-s-transferase 
GTP, guanosine 5’-triphosphate 
HDAC4, Histone deacetylase 4 
HEPES, n-2-hydroxyethylpiperazine-n'-2-ethanesulfonic acid 
HSF1, heat shock factor 1 
HSF2, heat shock factor 2 
IgG, immunoglobulin G 
IR, internal repeat  
kDa, kilodalton 
MDa, megadalton 
mRNA, messenger ribonucleic acid 
NLS, nuclear localization sequence 
nM, nanometer 
ORF, open reading frame 
PBS, phosphate buffered saline 
Pc, chromodomain of Polycomb, 
Pc2,  polycomb 2 protein 
PcG, Polycomb  
PCR, polymerase chain reaction 
PIAS, protein inhibitor of activated STAT 
PML, Progressive multifocal leukoencephalopathy 
PMSF, phenylmethanesulfonyl fluoride 
PRCs, Polycomb repressor complexes  
PREs, Polycomb Response Elements 
RanBP2, RAN binding protein 2 
RanGAP1, Ran GTPase-activating protein 
RING, Really Interesting New Gene 
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RNA, ribonucleic acid 
SDS, sodium dodecyl sulfate 
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SENP, SUMO1/sentrin specific peptidase 1 
SUMO, Small ubiquitin-like modifier  
TAF, TBP-associated factors  
TrxG, trithorax group 
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